Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00303277 · ClinicalTrials.gov registry record · Phase 4
Do HMG CoA Reductase Inhibitors Affect Abeta Levels?
A Phase 4 study, sponsored by Seattle Institute for Biomedical and Clinical Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
NCT00303277 is a Phase 4 study that has completed, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 35 participants.
The verdict
NCT00303277, a Phase 4 study, has completed, sponsored by Seattle Institute for Biomedical and Clinical Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
Study Summary
Recent evidence suggests that there is a significant overlap between AD and cerebrovascular disease. In fact, AD and cerebrovascular disease may share some of the same risk factors, including hypercholesterolemia. In addition, studies have suggested that the HMG Co-A reductase inhibitor lipid-lowering agents, known as "statins," decrease the risk of AD by up to 70%; however, effects differed by specific statin use. This study will compare two statins, simvastatin (which crosses the blood brain barrier) and pravastatin (which does not), with respect to their ability to alter blood and cerebrospinal fluid (CSF) levels of AD and inflammatory markers. The primary aim of the proposed study is to determine whether there is a reduction in Abeta with statins and whether the ability of the statin to cross the blood-brain barrier will affect its ability to decrease Abeta. If it can be demonstrated that statins alter AD-associated biomarkers, this would have broad implications for the treatment and prevention of AD.
Interventions
- DRUG pravastatin
- DRUG simvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2002-08 |
| Est. Completion | 2005-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00303277
The ClinicalTrials.gov registry entry for NCT00303277 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seattle Institute for Biomedical and Clinical Research, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pravastatin is the first listed.
NCT00303277 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00303277 about?
NCT00303277 is a clinical study titled "Do HMG CoA Reductase Inhibitors Affect Abeta Levels?". Recent evidence suggests that there is a significant overlap between AD and cerebrovascular disease. In fact, AD and cerebrovascular disease may share some of the same risk factors, including hypercholesterolemia. In addition, studies have suggested that the HMG Co-A reductase inhibitor lipid-loweri...
What is the current status of trial NCT00303277?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2002-08. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00303277?
The interventions under investigation include: pravastatin (DRUG), simvastatin (DRUG).
Who is sponsoring clinical trial NCT00303277?
This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.